3T Biosciences https://validator.w3.org/feed/docs/rss2.html Team 3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors John Leonard, MD Karen Knudsen, MBA, PhD Behzad Kharabi, MD 3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations Contract Clinical Trial Manager (Australia based) Research Associate – Immunology (Temporary / Contract) Sr Scientist – Immunology Contact Home 3T Biosciences Strengthens Leadership Team with Promotion of Marvin Gee, Ph.D., to Chief Research Officer and Appointment of Barbara Sennino, Ph.D., as Senior Vice President and Head of Early Development Jonathan MacQuitty, PhD Desmond Padhi, PharmD Barbara Sennino, PhD Marvin Gee, PhD News Eric Kaufman Careers Leah Sibener, PhD 3T Biosciences Builds Transatlantic Pan-Cancer Research Pipeline to Target Most Difficult-to-Treat Cancers Publications Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies Disclaimer 3T Biosciences Debuts with $40 Million Series A Financing Privacy Policy About Science 3T Biosciences Announces Appointment of John Leonard, M.D. to its Board of Directors Podcast Partnering David Piacquad, MBA Stefan Scherer, MD, PhD Terms of Service Stephen Schoenberger, PhD Christina Curtis, PhD, MSc Mark Davis, PhD Heinz-Josef Lenz, MD, PhD, FACP K. Christopher Garcia, PhD John Connolly, PhD Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies Beth Seidenberg, MD Christopher J DeRespino Susan Wong, MBA